Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 121Myeloid 62Lymphoid 31Plasma cell 9Thoracic 7Sarcoma 6Head & Neck 6Dermatologic 6Gastrointestinal 5Gynecologic 4Classical hematology 4CNS 4Genitourinary 3Other solid neoplasm 2Tumor-Agnostic 1Endocrine 1Breast 1

Conditions

Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Head and Neck Neoplasms 1Adenocarcinoma, Follicular 1

Interventions

Everolimus 15Magnetic Resonance Spectroscopy 8lutetium Lu 177 dotatate 7pasireotide 5gallium Ga 68 dotatate 5Cisplatin 5Specimen Handling 4Positron Emission Tomography Computed Tomography 4Nivolumab 4Fluorodeoxyglucose F18 4Carboplatin 4Temozolomide 3Paclitaxel 3Octreotide 3Lutetium-177 3Ga(III)-DOTATOC 3Etoposide 3(177)Lu-DOTA-EB-TATE 3vandetanib 2pembrolizumab 2olaparib 2fluorodopa F 18 2dabrafenib 2copper dotatate CU-64 2cemiplimab 2amino-acid, glucose, and electrolyte solution 2X-Rays 2Trastuzumab 2Radiotherapy 2Radiosurgery 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Azacitidine × Endocrine × Clear all
NCT00004062 2013-12-19

Azacitidine to Restore Thyroid Function in Patients With Persistent or Metastatic Thyroid Cancer

National Cancer Institute (NCI)

Phase 1 Completed
EndocrineHead & Neck

Thyroid Cancer, Papillary, Head and Neck Neoplasms, Thyroid Neoplasms, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡